|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:CEO
|
Jon P. Stonehouse
|
|
gptkbp:developedBy
|
oral small-molecule drugs
|
|
gptkbp:focusesOn
|
orphan drugs
rare diseases
|
|
gptkbp:foundedBy
|
Charles E. Bugg
William P. Sheridan
|
|
gptkbp:foundedIn
|
1986
|
|
gptkbp:headquartersLocation
|
gptkb:Durham,_North_Carolina,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BioCryst Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:numberOfEmployees
|
approximately 500
|
|
gptkbp:officeLocation
|
gptkb:Birmingham,_Alabama,_United_States
gptkb:Durham,_North_Carolina,_United_States
gptkb:Galway,_Ireland
|
|
gptkbp:product
|
gptkb:Rapivab
gptkb:Peramivir
BCX10013
BCX9250
BCX9930
Orladeyo
|
|
gptkbp:researchInterest
|
gptkb:paroxysmal_nocturnal_hemoglobinuria
gptkb:fibrodysplasia_ossificans_progressiva
immunology
infectious diseases
oncology
antiviral drugs
hematology
genetic diseases
autoimmune diseases
inflammatory diseases
kinase inhibitors
hematologic malignancies
structure-based drug design
complement system
rare pediatric diseases
enzyme inhibitors
COVID-19 therapeutics
complement factor D inhibitors
influenza therapeutics
oral therapies
|
|
gptkbp:specializesIn
|
gptkb:hereditary_hemorrhagic_telangiectasia
viral infections
complement-mediated diseases
|
|
gptkbp:subsidiary
|
BioCryst Pharmaceuticals Ireland Ltd.
|
|
gptkbp:tradedOn
|
NASDAQ:BCRX
|
|
gptkbp:website
|
https://www.biocryst.com/
|
|
gptkbp:bfsParent
|
gptkb:Baker_Bros._Advisors
gptkb:Peramivir
|
|
gptkbp:bfsLayer
|
7
|